Temporal Dynamics of Anti–Type 1 Interferon Autoantibodies in Patients With Coronavirus Disease 2019
Authors:
Open Access
- 7 December 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 75 (1) , e1192-e1194
Abstract
Binding levels and neutralization activity of anti–type 1 interferon autoantibodies peaked during acute coronavirus disease 2019 and markedly decreased thereafter. Most patients maintained some ability to neutralize type 1 interferon into convalescence despite lower levels of binding immunoglobulin G. Identifying these autoantibodies in healthy individuals before the development of critical viral disease may be challenging.Keywords
Funding Information
- Intramural Research Program
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (1ZIAAI001265, 1ZIAAI001265, 1ZIAAI001312, 1ZIAAI001270, 1ZIAAI001318)
- Regione Lombardia, Italy
This publication has 8 references indexed in Scilit:
- Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deathsScience Immunology, 2021
- Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet Respiratory Medicine, 2021
- Autoantibodies against type I IFNs in patients with life-threatening COVID-19Science, 2020
- Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiencyJournal of Clinical Investigation, 2015
- Anticytokine Autoantibody–Associated ImmunodeficiencyAnnual Review of Immunology, 2014
- Determination of Human Anticytokine Autoantibody Profiles Using a Particle-Based ApproachJournal of Clinical Immunology, 2011
- Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasiaBlood, 2010
- Anti-Interferon Autoantibodies in Autoimmune Polyendocrinopathy Syndrome Type 1PLOS Medicine, 2006